Show simple item record

dc.contributor.authorOu, S-H
dc.contributor.authorTiseo, M
dc.contributor.authorCamidge, R
dc.contributor.authorAhn, M
dc.contributor.authorHuber, R
dc.contributor.authorHochmair, M
dc.contributor.authorKim, S-W
dc.contributor.authorWest, H
dc.contributor.authorReckamp, K
dc.contributor.authorMolina, J
dc.contributor.authorLiu, G
dc.contributor.authorDelmonte, A
dc.contributor.authorViteri, S
dc.contributor.authorBearz, A
dc.contributor.authorSummers, Yvonne J
dc.contributor.authorReichmann, W
dc.contributor.authorKerstein, D
dc.contributor.authorGettinger, S
dc.contributor.authorKim, D-W
dc.date.accessioned2017-11-22T21:38:34Z
dc.date.available2017-11-22T21:38:34Z
dc.date.issued2017-09
dc.identifier.citation1345P Intracranial efficacy of brigatinib (BRG) in patients (Pts) with crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdx380.047
dc.identifier.urihttp://hdl.handle.net/10541/620667
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx380.047/4109402/1345PIntracranial-efficacy-of-brigatinib-BRG-inen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title1345P Intracranial efficacy of brigatinib (BRG) in patients (Pts) with crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases.en
dc.typeMeetings and Proceedingsen
dc.contributor.department"Chao Family Comprehensive Cancer Center, University of California Irvine School ofen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record